TKL Research Agrees to Sell Clinical Trials Division
TKL’s existing Research Clinics Division will continue to operate as TKL Research, Inc.
Rochelle Park, N.J. - TKL Research, a dermatology specialty clinical research organization (CRO), announced today that it has signed an agreement to sell its Clinical Trials Division (CTD) to QuintilesIMS. Upon closing, TKL’s CTD will become part of Novella Clinical, a Quintiles company. Moving forward, TKL Research will retain its Research Clinics Division (RCD) as TKL Research, Inc., which operates full-service inpatient and outpatient Phase I facilities in northern New Jersey.
The transaction, which is subject to standard and customary closing conditions, is expected to close in the fourth quarter of 2016.
“It’s exciting to see CTD take this next step in its strategic growth plan,” said
Serving as a full-service, global, dermatology CRO since 1995, TKL is headquartered in Rochelle Park, New Jersey and has offices in Fairlawn, New Jersey.
About TKL Research, Inc.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025